Biohaven Ltd.

Key metrics

Financial performance

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (265 filings)

Recent press releases

• Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare ...2025-01-07

  Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Biohaven is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and nonclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA (spinocerebellar ataxia); myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; antibody recruiting bispecific molecules and antibody drug conjugates for cancer. For more information, visit www.biohaven.com .

• Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia2024-09-20

  Conference call and webcast to be held Monday, September 23 , at 8:30am ET

• Biohaven Announces Closing of Public Offering and Full Exercise of ...2022-10-25

  Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Similar companies

The largest companies sharing Biohaven Ltd.'s SEC industry classification (pharmaceutical preparations).